InvestorsHub Logo

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Live Updating
profile icon
AliasUser1 Free
02/06/24 5:12 PM
profile icon
AliasUser1 Free
08/03/23 1:29 PM
profile icon
makinezmoney Free
12/30/22 11:19 AM
profile icon
TechandBio Free
12/29/22 8:38 PM
profile icon
TechandBio Free
12/25/22 9:54 PM
Bullish
Bullish
profile icon
makinezmoney Free
12/22/22 2:07 PM
profile icon
makinezmoney Free
12/22/22 9:54 AM
profile icon
makinezmoney Free
12/22/22 9:37 AM
Bullish
Bullish
profile icon
eddyimano Free
12/21/22 8:27 PM
profile icon
eddyimano Free
12/21/22 6:38 PM
profile icon
eddyimano Free
12/21/22 6:32 PM
profile icon
makinezmoney Free
12/21/22 10:43 AM
profile icon
eddyimano Free
12/21/22 12:26 AM
profile icon
BottomBounce Free
12/19/22 9:21 PM
Bearish
Bearish
profile icon
crudeoil24 PremiumMember
12/19/22 1:24 PM
profile icon
makinezmoney Free
12/19/22 11:48 AM
profile icon
makinezmoney Free
12/19/22 9:50 AM
profile icon
IOUBLOKE1 Free
12/19/22 7:25 AM
profile icon
Brokemillwright Free
02/11/22 9:01 PM
profile icon
roadkilll Free
02/09/22 2:04 PM
profile icon
Brokemillwright Free
01/31/22 10:31 AM
profile icon
Brokemillwright Free
01/31/22 10:16 AM
profile icon
Brokemillwright Free
01/31/22 12:43 AM
profile icon
roadkilll Free
12/07/21 9:27 PM
profile icon
roadkilll Free
10/28/21 3:36 PM
profile icon
RSummers Free
07/31/20 1:47 AM
profile icon
Trend-Setter Free
03/21/19 3:06 PM
profile icon
Trend-Setter Free
03/21/19 3:03 PM
profile icon
DMOST Free
02/18/19 1:36 PM
profile icon
DMOST Free
12/13/18 5:17 AM
profile icon
DMOST Free
12/08/18 10:30 PM
profile icon
DMOST Free
11/20/18 11:45 AM
profile icon
DMOST Free
11/15/18 3:33 AM
profile icon
DMOST Free
11/13/18 9:41 AM
profile icon
DMOST Free
11/13/18 9:38 AM
profile icon
DMOST Free
11/06/18 9:54 AM
profile icon
DMOST Free
10/19/18 4:24 PM
profile icon
DMOST Free
10/03/18 3:43 PM
profile icon
DMOST Free
09/27/18 8:31 AM
profile icon
DMOST Free
09/20/18 9:12 PM
profile icon
DMOST Free
09/19/18 12:13 PM
profile icon
DMOST Free
09/19/18 12:12 PM

Madrigal Pharmaceuticals Inc (MDGL) RSS Feed

Followers
17
Posters
35
Posts (Today)
0
Posts (Total)
162
Created
07/25/16
Type
Free
Moderators

 
WEBSITE: http://www.madrigalpharma.com


NEW MADRIGAL/SYNTA CORPORATE PRESENTATION:

http://www.madrigalpharma.com/wp-content/uploads/2016/05/Synta-Madrigal-Corporate-Slide-Deck-2060501.pdf
Madrigal Pharmaceuticals is developing novel, high-quality small-molecule drugs addressing major unmet needs in cardiovascular and metabolic diseases. The Company is targeting treatment of both niche and prevalent indications, including fatty liver disease and non-alcoholic steatohepatitis (NASH), diabetes, dyslipidemia and cardiovascular disease. Madrigal’s lead drug candidate is MGL-3196, a Phase 2 ready orally administered liver-directed thyroid hormone receptor-ß (THR-ß) agonist. In Madrigal’s 14-day multiple dose Phase 1 study in healthy volunteers with mildly elevated LDL cholesterol, MGL-3196 demonstrated safety and excellent tolerability at all doses tested. In the multiple dose study, MGL-3196 demonstrated proof-of-concept for lipid lowering including dose-dependent, highly significant, up to 30% lowering of LDL cholesterol and non-HDL cholesterol, and a strong trend of up to 60% triglyceride lowering. These results suggest that MGL-3196 has a unique lipid lowering profile as compared with other agents and a potential to significantly reduce cholesterol, triglycerides and liver triglycerides. Elevated cholesterol, triglycerides and fatty liver are an underlying cause of many metabolic and cardiovascular diseases, which, themselves, are associated with increased mortality.

In addition, MGL-3196 is a NASH target supported by compelling human biology and genetics. NASH is a serious liver disease found in individuals with fatty liver disease that is associated with hypothyroidism, diabetes, obesity, and dyslipidemia. MGL-3196 Phase 1 human data demonstrate safety and benefit in NASH-related dyslipidemia, and data from MGL-3196 treated NASH animal models support efficacy in NASH at doses relevant to humans.
 
New Post